[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-413792-105":59,"doc-detail-413792-en":131},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":124,"head_meta":126,"extra_data":128,"updated_unix":130},105,"en","the-intersection-of-heart-failure-and-iron-deficiency-anemia-diagnostic-and-therapeutic-approaches","The Intersection of Heart Failure and Iron Deficiency Anemia - Diagnostic and Therapeutic Approaches","","Iron deficiency anemia (IDA) is highly prevalent among individuals with heart failure (HF), affecting 40–70% of patients and functioning as an important prognostic marker. IDA is tied to oxidative metabolism and myocardial cell damage, worsening HF symptoms such as reduced exercise capacity, lower quality of life, and increased cardiovascular morbidity. The review addresses diagnosis, treatment, outcomes, prognostic indicators, and future challenges. Intravenous iron is emphasized for improving function and reducing hospitalizations, while individualized dosing and research refinement remain central.",{"@graph":69,"@context":123},[70,84,106],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":35,"@type":76,"position":81},"https://docshare.wps.com/document/healthcare/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/the-intersection-of-heart-failure-and-iron-deficiency-anemia-diagnostic-and-therapeutic-approaches/413792/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/the-intersection-of-heart-failure-and-iron-deficiency-anemia-diagnostic-and-therapeutic-approaches/413792.png","ImageObject",300,407,{"name":92,"@type":93},"Jiven","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-03","2026-09-28",true,{"@type":102,"interactionType":103,"userInteractionCount":105},"InteractionCounter",{"@type":104},"ViewAction",14,{"@type":107,"mainEntity":108},"FAQPage",[109,115,119],{"name":110,"@type":111,"acceptedAnswer":112},"How common is iron deficiency anemia among patients with heart failure?","Question",{"text":113,"@type":114},"IDA is reported as affecting about 40–70% of HF patients. It is also noted as common in chronic HF (30–50%) and in acute HF (up to 80%).","Answer",{"name":116,"@type":111,"acceptedAnswer":117},"What clinical impact does IDA have on heart failure outcomes?",{"text":118,"@type":114},"IDA is associated with more severe HF symptoms, poorer clinical outcomes, reduced exercise capacity, diminished quality of life, and higher cardiovascular morbidity, including more adverse prognostic implications.",{"name":120,"@type":111,"acceptedAnswer":121},"Why is intravenous iron therapy highlighted compared with oral iron?",{"text":122,"@type":114},"Oral iron can reduce mortality and hospitalizations but may not improve exercise capacity or quality of life and can be limited by side effects. Intravenous iron is described as more effective for improving hematological and functional parameters and reducing HF hospitalizations.","https://schema.org",{"og:url":83,"og:type":125,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":127,"canonical":83},"index,follow",{"doc_id":129,"site_id":62},413792,1790739524,{"code":4,"msg":5,"data":132},{"doc_id":129,"user_id":133,"nickname":92,"user_avatar":134,"doc_module":4,"category_id":34,"category_name":35,"doc_title":65,"doc_description":67,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":105,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":105,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":4},1099513958607,"https://ap-avatar.wpscdn.com/avatar/100002390cf8733938c?x-image-process=image/resize,m_fixed,w_180,h_180&k=1778829742770036399","Send Orders for Reprints [to reprints@benthamscience.net](to reprints@benthamscience.net)  \nCurrent Cardiology Reviews, 2025, 21, e1573403X331380  \nCurrent Cardiology Reviews  \nMaleesha Bw Thammitage 1, Naji Moussa2, Ali Rezvani3, Damandeep Kaur Dhillon4, Miryam Lisseth Obando Gamarra5, Kanwaraj Singh6, Abdul Hawwa7, Alejandra Felix Vincente8, Sehajpreet Kaur9, Kiranmayee Seshasai Nemalapuri 10, Devika Poonwassie 11 and Manju Rai 12,*  \n1Aloka Medical Center, Horona, Ratnapura, Sri Lanka; 2Department of Cardiology, Richmond Gabriel University, Kingstown, St. Vincent, Caribbean; 3School of Medicine, Case Western Reserve University, Cleveland, OH 44106, USA; 4Saint James School of Medicine, Dallas, TX 75238, USA; 5 Universidad Andina del Cusco, Cusco, Peru; 6Maharishi Markendeshwar Institute of Medical Sciences and Research, Ambala, Haryana, India; 7School of Medicine, St. George’s University, Grenada, West Indies; 8Department of Internal Medicine, Universidad de Sonora, Sonora, Mexico; 9Punjab Institute of Medical Sciences, Jalandhar, Punjab, India; 10Massachusetts College of Pharmacy and Health Sciences, Boston, MA 02115, USA; 11Department of Internel Medicine, University of West Indies, St. Augustine, Trinidad and Tobago; 12Department of Medical Biotechnology, Shri Venkateshwara University, Gajraula, Ludhiana, Uttar Pradesh, India  \nAbstract: Iron deficiency anemia (IDA) is highly prevalent among individuals with heart failure (HF), impacting 40-70% of patients and serving as a significant prognostic indicator. Linked with oxidative metabolism and myocardial cell damage, IDA exacerbates HF symptoms, including reduced exercise capacity, diminished quality of life, and heightened cardiovascular morbidity. This review explores the diagnosis, treatment, clinical outcomes, prognostic indicators, and forthcoming challenges associated with IDA in HF patients. Crucially, addressing IDA in HF is critical for enhancing prognosis, including clinical outcomes, quality of life, hospitalizations, and survival rates. While oral iron therapy shows efficacy in reducing mortality and hospitalizations, it falls short in improving exercise capacity and quality of life, often deterring patients due to side effects. In contrast, intravenous (IV) iron therapy is highly effective in enhancing hematological parameters, functional capacity, and reducing HF hospitalizations. Optimizing IV iron dosing based on individual patient characteristics is essential for balancing treatment efficacy and adverse effects. Emphasizing individualized approaches, with IV iron emerging as a superior option, underscores the necessity for ongoing research to refine dosing strategies and explore novel therapies. Compliance remains paramount for positive outcomes with IDA treatment, with oral supplementation being cost-effective and easily accessible. However, parenteral supplementation proves beneficial for patients intolerant to oral therapy. Addressing IDA through tailored interventions, including oral or parenteral supplementation, is pivotal in averting complications and improving outcomes in HF patients. This paper consolidates insights into the diagnosis, treatment, impact, pathophysiology, clinical outcomes, research gaps, and future directions concerning IDA in HF patients, drawing on extensive literature to offer a comprehensive understanding of this critical issue.  \nKeywords: Heart failure, iron deficiency anemia, prognosis, clinical outcomes, intravenous iron therapy, individualized approach.  \n1. INTRODUCTION  \nIron deficiency anemia (IDA) impacts 30-50% of individuals with chronic heart failure [1] . Iron deficiency is prevalent in up to 80% of patients experiencing acute heart failure [2, 3] . The World Health Organization (WHO) defines anemia as hemoglobin levels below 13.0 g/dL in adult males and below 12.0 g/dL in adult females. Iron deficiency  \n*Address correspondence to this author at the Department of Medical Biotechnology, Shri Venkateshwara Univers","cbCaijbTyg1csyps","https://ap.wps.com/l/cbCaijbTyg1csyps","pdf",20845233,"English","# Introduction\n## Iron deficiency anemia in heart failure\n## Definitions and pathophysiology\n## Heart failure overview and clinical linkage\n# Diagnostic and therapeutic approaches\n## Treatment outcomes and prognosis\n## Oral vs intravenous iron considerations\n## Individualized dosing and future challenges","[{\"question\":\"How common is iron deficiency anemia among patients with heart failure?\",\"answer\":\"IDA is reported as affecting about 40–70% of HF patients. It is also noted as common in chronic HF (30–50%) and in acute HF (up to 80%).\"},{\"question\":\"What clinical impact does IDA have on heart failure outcomes?\",\"answer\":\"IDA is associated with more severe HF symptoms, poorer clinical outcomes, reduced exercise capacity, diminished quality of life, and higher cardiovascular morbidity, including more adverse prognostic implications.\"},{\"question\":\"Why is intravenous iron therapy highlighted compared with oral iron?\",\"answer\":\"Oral iron can reduce mortality and hospitalizations but may not improve exercise capacity or quality of life and can be limited by side effects. Intravenous iron is described as more effective for improving hematological and functional parameters and reducing HF hospitalizations.\"}]","The Intersection of Heart Failure and Iron Deficiency Anemia - Diagnostic and Therapeutic Approaches | PDF",1790595777,35]